TGFB1 and neoplasm: Tregs suppress effector T cell activity through various mechanisms, including the secretion of immunosuppressive cytokines (e.g., IL-10 and TGF-β) and the expression of immune checkpoint proteins (e.g., CTLA-4 and PD-1) [36,37,38], thereby allowing tumor cells to evade immune surveillance.